Modality
ASO
MOA
WRNi
Target
FcRn
Pathway
Angiogenesis
CFSCD
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
Feb 2020
→ Mar 2026
Phase 1Current
NCT05332938
1,819 pts·SCD
2020-02→2026-03·Recruiting
NCT03730001
32 pts·SCD
2020-10→TBD·Active
1,851 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-211w agoPh2 Data· SCD
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1/2
Recruit…
P1/2
Active
Catalysts
Ph2 Data
2026-03-21 · 1w ago
SCD
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05332938 | Phase 1/2 | SCD | Recruiting | 1819 | Safety |
| NCT03730001 | Phase 1/2 | SCD | Active | 32 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Sovafutibatinib | Moderna | Approved | FcRn |